Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.68 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | PTGIR | P43119 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30169776 | 0.93 | PTGDR2 (0.59) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1921943 | 0.92 | PTGDR2 (0.60) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL138775 | 0.89 | PTGDR2 (0.75) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL155538 | 0.88 | PTGDR2 (0.71) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL15658878 | 0.88 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1922281 | 0.88 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL16501863 | 0.87 | PTGDR2 (0.54) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL1921683 | 0.87 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL153883 | 0.87 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL13746165 | 0.87 | PTGDR2 (0.69) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| EP-2461809-A2 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | Panmira Pharmaceuticals, LLC (US) | 2012-06-13 | — | — | EP | claimed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-8049015-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-11-01 | — | — | US | claimed |
| CN-102164894-A | Heteroaryl antagonists of prostaglandin D2 receptors | AMIRA PHARMACEUTICALS INC | 2011-08-24 | — | — | CN | claimed |
| EP-2328869-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | claimed |
| WO-2011014587-A2 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | claimed |
| WO-2010037054-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-8785393-B2 | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2480225-A2 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | Panmira Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2461809-A2 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | Panmira Pharmaceuticals, LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2010037054-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PTGER2, P2RY2, TBXA2R | PTGDR2 5/4885TBXA2R 3/4885PTGDR 13/4885 |
| US-20100081673-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 6/4885PTGDR 1/4885 |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | BDKRB2, TRPV2, CYSLTR2 | PTGDR2 14/4885TBXA2R 7/4885PTGDR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.